Deans' stroke musings: Brain Connectivity Patterns Link Vascular Disease to Cognitive Decline

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, January 13, 2025

Brain Connectivity Patterns Link Vascular Disease to Cognitive Decline

How will your competent? doctor EXACTLY PREVENT THIS POST STROKE? NO plan? So, you don't have a functioning stroke doctor, do you?

Brain Connectivity Patterns Link Vascular Disease to Cognitive Decline

Summary: Researchers have identified how cerebrovascular disease (CeVD) disrupts brain connectivity, contributing to cognitive decline and neurodegeneration alongside Alzheimer’s disease (AD). By studying brain networks and blood biomarkers in older adults, they discovered distinct but additive effects of CeVD and AD-related markers on cognition and brain atrophy. CeVD acts as a global disruptor of brain communication networks, while AD markers, such as plasma p-tau181, follow separate pathways.

These findings emphasize the potential of combining neuroimaging and blood biomarkers for early detection and monitoring of dementia(Useless! Where is the prevention protocol? Oh, you incompetently haven't done that research?). The study provides new insights into the independent roles of CeVD and AD in driving cognitive and structural brain changes. Future research aims to refine brain connectivity markers for earlier predictions and targeted interventions.

Key Facts:

Dual Pathways: CeVD and AD markers independently and additively affect cognition and brain atrophy but do not synergize.
Brain Connectivity Impact: CeVD disrupts global brain network communication, influencing cognitive decline.
Predictive Biomarkers: Neuroimaging and blood-based markers show promise for early dementia risk assessments.

Source: NUS

Researchers have uncovered novel insights into how brain function disruptions related to cerebrovascular disease (CeVD) interact with Alzheimer’s disease (AD) pathology to impact neurodegeneration and cognition in older adults.

Led by Associate Professor Juan Helen Zhou, Director of the Centre for Translational Magnetic Resonance Research, Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), the research team revealed a brain functional connectome phenotype that is related to multiple CeVD markers and contributes additively to cognitive decline and neurodegeneration alongside AD.

This shows a brain. — While the two factors contributed additively to longitudinal cognitive decline and brain atrophy, the study found no evidence of a synergistic relationship between CeVD and p-tau181, suggesting that these factors may influence neurodegeneration in distinct pathways. Credit: Neuroscience News

The study highlights CeVD as a global disruptor of brain connectivity, reshaping our understanding of its role in dementia.

CeVD, often co-occurring with AD, has long been a significant area of study in ageing and dementia research. It refers to a group of conditions that affect the blood vessels and blood flow in the brain, such as stroke, cerebral atherosclerosis (narrowing or hardening of larger brain arteries due to plaque buildup), and small vessel disease that affects the tiny blood vessels in the brain.

These conditions can lead to brain damage by disrupting the delivery of oxygen and nutrients, which are essential for normal brain function.

In the study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the team examined the brain’s functional organisation in 529 older adult participants across the dementia spectrum, ranging from those with healthy cognition to individuals diagnosed with AD.

Analyzing how the different markers of CeVD and brain activity patterns correlate with affecting the participants, the team identified a global functional connectome phenotype, or a unique pattern in the brain’s communication network, that is strongly associated with high levels of the burden of four markers of CeVD seen on brain scans.

A key finding of the study was the identification of divergent effects of p-tau181, a blood-based biomarker for AD, and CeVD-related functional connectome phenotype on cognitive decline and brain atrophy.

While the two factors contributed additively to longitudinal cognitive decline and brain atrophy, the study found no evidence of a synergistic relationship between CeVD and p-tau181, suggesting that these factors may influence neurodegeneration in distinct pathways.

A/Prof Zhou said, “We discovered that a CeVD-related brain network phenotype, along with a key Alzheimer’s disease blood biomarker, can provide powerful insights into the future trajectory of cognitive decline and neurodegeneration.

“Our findings highlight the potential of brain connectome-based markers to track cognitive decline, particularly for individuals at-risk for dementia, and underscore the importance of integrating neuroimaging and blood biomarkers to better understand the pathophysiology of these co-occurring diseases.”

Dr Joanna Su Xian Chong, senior research fellow from A/Prof Zhou’s group, who is also first author of the study, added, “This pattern shows how the burden of multiple cerebrovascular disease markers can collectively exert widespread influences on brain function.

“Importantly, the combination of this pattern linked to CeVD and plasma p-tau181, a marker of Alzheimer’s disease, had independent and additive effects on long-term outcomes.

“Together, they contributed to cognitive decline and increased brain atrophy at baseline and over time, but did not interact directly to amplify each other’s effects.”

Both A/Prof Zhou and Dr Chong are also from the Centre for Sleep and Cognition and Healthy Longevity & Human Potential Translational Research Programmes at NUS Medicine.

Moving forward, the team aims to explore how the brain communication pattern linked to CeVD is affected by the severity, cause, and location of CeVD markers throughout the progression of the disease.

They also plan to investigate how this pattern interacts with different AD markers to contribute to brain degeneration and decline in multiple cognitive domains. Additionally, they aim to determine if these brain network features can be used as a reliable biomarker to monitor current and future cognitive decline, particularly in individuals at risk for dementia.

These features could offer more precise predictions than traditional brain imaging methods and help identify long-term cognitive outcomes earlier.

Their goal is to better understand the brain mechanisms behind CeVD and AD to develop advanced imaging tools for early detection and disease monitoring.

Funding: This research is supported by the National Research Foundation, Singapore under the NMRC Open Fund – Large Collaborative Grant (MOH-000500) and administered by the Singapore Ministry of Health through the NMRC Office, MOH Holdings Pte Ltd.

Participants for the study were recruited from the National University Hospital and St Luke’s Hospital.